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Multiple myeloma (MM) accounts for 1 % of all cancer deaths. Although treated aggressively, almost all myelomas eventually recur
and become resistant to treatment. Atiprimod (2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate) has
exerted anti-inflammatory activities and inhibited oeteoclast-induced bone resorption in animal models and been well tolerated in
patients with rheumatoid arthritis in phase I clinical trials. Therefore, we investigated its activity in MM cells and its mechanism of
action. We found that Atiprimod inhibited proliferation of the myeloma cell lines U266-B1, OCI-MY5, MM-1, and MM-1R in a time-
and dose-dependent manner. Atiprimod blocked U266-B1 myeloma cells in the G0/G1 phase, preventing cell cycle progression.
Furthermore, Atiprimod inhibited signal transducer and activator of transcription (STAT) 3 activation, blocking the signalling pathway
of interleukin-6, which contributes to myeloma cell proliferation and survival, and downregulated the antiapoptotic proteins Bcl-2,
Bcl-XL, and Mcl-1. Incubation of U266-B1 myeloma cells with Atiprimod induced apoptosis through the activation of caspase 3 and
subsequent cleavage of the DNA repair enzyme poly(adenosine diphosphate-ribose) polymerase. Finally, Atiprimod suppressed
myeloma colony-forming cell proliferation in fresh marrow cells from five patients with newly diagnosed MM in a dose-dependent
fashion. These data suggest that Atiprimod has a role in future therapies for MM.
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Multiple myeloma (MM) is a clonal B-cell neoplasm characterised
by an accumulation of neoplastic plasma cells. Multiple myeloma
accounts for 1% of all cancer deaths and affects approximately
14500 Americans each year (Jemal et al, 2003). For many years,
intermittent courses of melphalan and prednisone constituted the
standard therapy for MM. Several other drugs, including alkylating
agents, vinca alkaloids, and, in recent years, thalidomide and its
derivatives, and the proteasome inhibitor bortezomib, have been
studied with various degrees of success (Dimopoulos et al, 2003;
Anderson, 2004). However, almost all myelomas eventually recur
and become resistant to treatment (Dimopoulos et al, 2003). Thus,
the search for more effective agents continues.
Several studies have demonstrated that of all B-cell-stimulating
factors, interleukin (IL)-6 plays the most important role in MM by
regulating the growth and survival of the neoplastic cells (Kawano
et al, 1988; Klein et al, 1995; Cote et al, 2002). Interleukin-6 has
been implicated in the pathogenesis of MM (Klein et al, 1995). This
cytokine, which is produced by both myeloma and bone marrow
(BM) stroma cells, stimulates MM cell proliferation in an autocrine
and paracrine fashion (Klein et al, 1995; Chauhan et al, 1996),
augments osteoclast activity (Szczepek et al, 2001), and provides
the neoplastic cells with a survival advantage (Lichtenstein et al,
1995). Indeed, serum IL-6 levels in patients with MM have been
shown to be correlated with disease stage, activity, and survival
(Klein et al, 1990). Thus, the inhibition of IL-6 activity may be an
adequate strategy for suppressing MM cells.
Atiprimod (SK&F 106615; Callisto Pharmaceuticals, New York,
NY, USA) is an azaspirane, a cationic amphiphilic compound, with
anti-inflammatory activity. Several azaspiranes have been found
to be beneficial in animal models of adjuvant induced arthritis
(Bradbeer et al, 1996), autoimmune encephalitis (Badger et al,
1989), lupus erythematosus (Albrightson-Winslow et al, 1990),
autoimmune diabetes mellitus (Rabinovitch et al, 1993), and solid
organ transplantation graft rejection (Badger et al, 1991; Fan et al,
1993). Although azaspiranes have been studied extensively, their
mechanism of action is not completely understood. Several
mechanisms, including the upregulation of nonspecific (Badger
et al, 1990a,b) and splenic (Badger et al, 1990a,b; Schmidbauer
et al, 1993) suppressor cell activity and downregulation of various
cytokine receptors (e.g. IL-2 receptor, transferrin receptor),
adhesion molecules (e.g., ICAM-1), and cytokines (e.g. IL-2,
interferon-g, IL-1, tumour necrosis factor-a, and IL-6) have been
reported (Schmidbauer et al, 1993). These mechanisms and the
ability of azaspiranes to normalise bone mineral density, prevent
structural damage to joints and periarticular bone, and down-
regulate serum IL-6 levels (Bradbeer et al, 1996) without inducing
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smyelotoxicity (King et al, 1991) suggest that these compounds may
be effective against autoimmune disorders and diseases causing
bone destruction. Therefore, Atiprimod was administered to
patients with rheumatoid arthritis in phase I clinical trials and
found to be well tolerated.
Owing to Atiprimod’s broad array or activities, we speculated
that Atiprimod would inhibit MM cells by suppressing the
activity of IL-6. We found that Atiprimod blocked the activation
of the signal transducer and activator of transcription (STAT) 3,
inhibited myeloma cell proliferation, and induced cell cycle arrest
and apoptosis in MM cells.
MATERIALS AND METHODS
Patients
Bone marrow (BM) aspirates were obtained from five patients with
newly diagnosed MM (Table 1). All studies were performed with
the patients’ informed consent and were approved by the
Institutional Review Board at The University of Texas M.D.
Anderson Cancer Center, Houston, TX, USA.
Cell lines
The MM cell lines MM-1, U266-B1, and RPMI-8226 were obtained
from the American Type Culture Collection (ATCC; Rockville,
MD, USA), MM-1R cells (a dexamethazone-resistant variant of
the MM-1 line) were provided by Steven Rosen (Northwestern
University Medical School, Chicago, IL, USA), and the cell line
OCI-MY5 was provided by Hans Messner (Ontario Cancer
Institute, Toronto, ON, Canada). MM-1, MM-1R, and U266-B1
cell lines were maintained in RPMI 1640 (Sigma Chemical Co., St
Louis, MO, USA) supplemented with 10% fetal calf serum (FCS;
Hyclone, Logan, UT, USA). OCI-MY5 cells were maintained in
Iscove’s modified Dulbecco’s medium (IMDM) supplemented with
10% FCS. The KM102 marrow stroma cell line was established
from normal BM (Harigaya and Handa, 1985) and maintained in
RPMI 1640 supplemented with 10% FCS.
Drug preparation
Atiprimod (Callisto Pharmaceuticals, New York, NY, USA) was
dissolved in phosphate-buffered saline (PBS; GIBCO BRL, Grand
Island, NY, USA) at a final concentration of 8mM. The stock
solution was further diluted in tissue culture medium.
Enzyme-linked immunosorbent assay (ELISA)
Enzyme-linked immunosorbent assays were performed with IL-6
and IL-6 receptor (IL-6R) ELISA kits (Biosource International,
Camarillo, CA, USA). In one experiment, U266-B1 cells were
harvested at the logarithmic phase of their growth, washed twice in
RPMI 1640, and incubated in RPMI 1640 supplemented with 10%
FCS at 371C with or without 2mM Atiprimod. Supernatant samples
were harvested at 1, 6, 8, and 16h after incubation. In another
experiment, myeloma cell lines were incubated for 72h with or
without either normal marrow stroma or KM102 stroma cells in
the presence or absence of Atiprimod. Supernatant samples were
harvested and both IL-6 and soluble IL-6R levels were analysed in
accordance with the manufacturer’s instructions. Briefly, super-
natant samples were added to the wells in duplicate and incubated
for 2h at 371C. The test wells were then washed three times in PBS,
incubated with rabbit IL-6 antiserum for 2h, washed as previously
described, and incubated for 30min with goat anti-rabbit IgG
conjugated to horseradish peroxidase. The test wells were
vigorously washed, a substrate, provided by the manufacturer,
was added, and the colour intensity was read within 15min at a
wavelength of 490nm with a microplate reader.
Electrophoretic mobility shift assay for analysis of NF-jB
activation
NF-kB activation was analysed by electrophoretic mobility gel shift
assay (EMSA) as described previously (Chaturvedi et al, 2000). In
brief, 8-mg nuclear extracts prepared from treated or untreated
U266-B1 cells were incubated with a
32P-end-labelled 45-mer
double-stranded NF-kB oligonucleotide from the human immu-
nodeficiency virus-1 long terminal repeat (50-TTGTTACAAGG
GACTTTCCGCT GGGGACTTTCCAG GGAGGCGTGG- 30) for
15min at 371C, and the DNA–protein complex was resolved on
a 6.6 % native polyacrylamide gel. The radioactive bands from the
dried gels were visualised and quantitated by a PhosphorImager
(Molecular Dynamics, Sunnyvale, CA, USA) with the ImageQuant
software program.
Western immunoblotting
Cell lysates were assayed for their protein concentration using
the BCA protein assay reagent (Pierce Chemical, Rockford, IL,
USA). Each set of paired lysate samples was then adjusted to have
the same protein concentration. Sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS–PAGE) (Laemmli, 1970)
was conducted at constant wattage (10W) in running buffer cooled
to 41C. Stacking gels contained 4% (wtvol
 1) acrylamide, and
separating gels contained 12% (wt/vol) acrylamide. Approximately
50mg of sample protein was loaded into each lane. Proteins
separated with SDS–PAGE were transferred to nitrocellulose
membranes; the transfers were performed overnight at 30V in a
cooled (41C) reservoir containing 25mM Tris (tris (hydroxy-
methyl) aminomethane), 192mM glycine, and 20% methanol (pH
8.3) (Towbin et al, 1979) transfer buffer. The nitrocellulose
membranes were then removed from the blot apparatus and
placed in a solution of Ponceau S stain (0.5% Ponceau S and 1%
glacial acetic acid in water) to verify equal loading of protein in the
control and treated samples (Gershoni and Palade, 1983).
After membranes were stained for 5min, they were rinsed for
2min and examined. Equal loading of protein was verified, and the
membranes were then rinsed for an additional 10min and
immunoscreened. The membranes were blocked with BLOTTO
(5% dried milk dissolved in 50ml of PBS) for at least 1h at room
Table 1 Clinical data on MM patients
Patient Age/sex MM Type Hb (gdl
 1)
WBC
( 10
9l
 1)
Platelets
( 10
9l
 1)
%B M
myeloma cells
Serum paraprotein
(gdl
 1)
Urine paraprotein
(g24h
 1)
1 44/F IgG 9.4 10.3 322 55 6.1 1.0
2 48/F IgA 6.9 6.0 45 70 3.5 0.4
3 56/M IgG 12.4 5.9 254 36 3.4 0.16
4 48/M IgG 10.1 13.2 231 58 6.8 1.2
5 59/M IgA 12.5 4.8 181 44 3.4 0.1
F¼female; M¼male; MM¼multiple myeloma; Hb¼haemoglobin; WBC¼white blood cells; BM¼bone marrow.
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stemperature. They were then washed three times in PBS plus 0.5%
Tween 20. Next, the membranes were incubated for 1 to 12h with
the appropriate antibodies. After incubation, the membranes were
rinsed three times in PBS containing 0.5% Tween 20 for 15min
each. The bound antibody was detected with the ECL Western
blotting detection system (Amersham, Arlington Heights, IL,
USA). The membranes were incubated with an anti-rabbit and
anti-mouse horseradish peroxidase-labelled antibody at a concen-
tration of 1:200 and 1:1750, respectively, in PBS plus 0.5% Tween
20 at room temperature for 1h. After this incubation, the
membranes were washed in PBS containing 0.5% Tween 20, and
bound antibody was detected using the ECL protocol. Chemi-
luminescence of the membranes was detected with X-OMAT AR5
X-ray film (Kodak, Rochester, NY, USA) in stainless steel exposure
cassettes (Sigma).
The following antibodies were used: monoclonal mouse anti-
human CPP32 (Trasduction Laboratories, Lexington, KY, USA) for
detection of procaspase 3, rabbit anti-human cleaved caspase 3
(New England Bio Labs, Beverly, MA, USA), mouse anti-human
poly(ADP-ribose) polymerase (PARP; Pharmingen, San Diego, CA,
USA), mouse anti-human Bcl-2 (Transduction Laboratories,
Lesington, KY, USA), rabbit anti-human Bcl-XL (Transduction
Laboratories), mouse anti-human Mcl-1 (Pharmingen), and mouse
anti-human STAT3 and pSTAT3 antibodies (Upstate Cell Signaling
Solutions, Charlottesville, VA, USA). Normal mouse immuno-
globulin G (IgG) and rabbit IgG (Sigma) were used as controls. To
confirm the detection of these proteins, we used lysates of Jurkat
cells (ATCC) for the detection of procaspase 3, PARP, STAT3,
pSTAT3, and Bcl-2; Hela cells (ATCC) for the detection of cleaved
caspase 3; and human endothelial cells for the detection of Bcl-XL.
Electrophoretic mobility shift assay for STAT3-DNA
binding
The STAT3-DNA binding was analysed by EMSA using a
32P-
labelled high-affinity sis-inducible element (hSIE) probe as
previously described (Yu et al, 1995). Briefly, 2 10
6 U266-B1
cells were incubated with 8mM Atiprimod for 0.5, 1, 2, 4, and 8h.
Nuclear extracts were prepared and labelled with hSIE probe
(50-CTTCATTTCCCGTAAATCCCTAAAGCT-30 and 50-AGCTTTA
GGGATTTACGGGAAATGA-30), and STAT3-DNA binding was
analysed using EMSA as described above.
MTT assay
The 3,(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTT) assay was performed
using an MTT-based cell proliferation/cytotoxicity assay system
(Promega, Madison, WI, USA). Briefly, U266-B1, MM-1, MM-1R,
OCI-MY5, and RPMI-8266 cells were harvested at the logarithmic
phase of their growth and fresh low-density MM marrow cells
(containing 440% myeloma cells) were isolated by gradient
centrifugation. They were then washed twice in RPMI 1640
containing 10% FCS and counted in a hemocytometer, and their
viability was determined using 0.1% trypan blue staining. Equal
numbers of viable cells (5 10
4 cells per well) were incubated in a
total volume of 100ml of RPMI 1640 medium supplemented with
10% FCS alone or with Atiprimod at increasing concentrations; the
incubations were continued for 72h in 96-well flat-bottomed plates
(Linbro; Flow Laboratories, McLean, VA, USA) at 371Ci na
humidified 5% CO2 atmosphere. In another experiment, the cells
were incubated for 24, 48, and 72h. After incubation, 20mlo f
CellTiter96 One Solution Reagent (Promega) was added to each
well. The plates were then incubated for an additional 60min at
371C in a humidified 5% CO2 atmosphere. Immediately after
incubation, absorbance was read using a 96-well plate reader at a
wavelength of 490nm. Each data point was determined six times
before analysis.
Cell cycle analysis
Cell cycle analysis was performed according to standard protocols.
Briefly, 5 10
6 cells were pelleted after incubation with Atiprimod.
The cell pellets were washed and resuspended in 2ml of 1%
paraformaldehyde in PBS. Cells were incubated for 15min at 41C
and then washed again in PBS, resuspended in 2ml of absolute
ethanol, and stored at  201C until staining. Next, the stored cells
were washed twice in PBS, resuspended in 0.5ml of propidium
iodide (PI) staining buffer (50mg/ml PI and 10mg/ml RNase in
PBS), and then incubated for 1h at room temperature in total
darkness. Flow cytometric analysis was performed using a
FACSCalibur flow cytometer and the CellQuest software program
(Becton Dickinson Immunocytometry Systems, San Jose, CA,
USA). Data analysis was performed using CellQuest and the Modfit
LT V2.0 software program (Verity Software House, Topsham, ME,
USA).
Apoptosis assays
To quantify the percentage of cells undergoing apoptosis, we used
annexin V-CY5 (Pharmingen, San Diego, CA, USA) as previously
described (Vermes et al, 1995). Briefly, Atiprimod-treated U266
cells were washed twice with cold PBS and then resuspended in
binding buffer (10nM HEPES (N-2-hydroxyethylpiperazine-N-2-
ethanesulphonic acid), 140nM NaCl, and 5nM CaCl2, pH 7.4) at a
concentration of 1 10
6 cells ml
 1. After incubation, 100ml of the
solution was transferred to a 5-ml culture tube to which 5mlo f
annexin V-CY5 and 10ml of PI were added. The tube was gently
vortexed and incubated for 15min at room temperature in total
darkness. At the end of the incubation, 400ml of binding buffer was
added to the tube, and the cells were analysed immediately by
flow cytometry. Flow cytometric analysis was performed with a
FACSCalibur flow cytometer using CellQuest. Data analysis was
performed with CellQuest and Modfit LT V2.0.
To establish that Atiprimod induces apoptosis in MM cells, we
used the TdT-mediated dUTP nick-end labelling (TUNEL)
apoptosis detection system (Promega) as previously described
(Estrov et al, 1999). Briefly, U266 cells were incubated with 6mM
Atiprimod for 2h in the presence or absence of a 50mM
concentration of the caspase inhibitor Ac-DEVD-CHO (Thornber-
ry et al, 1994) (CalBiochem, La Jolla, CA, USA). Formaldehyde-
treated cytospun cells were made permeable with 0.2% Triton
X-100 in PBS. After being washed, the slides were treated with
equilibration buffer (supplied with the TUNEL kit) and then
incubated with TdT buffer (prepared according to the manufac-
turer’s instructions) for 60min. The staining reaction was
terminated by treating the slides with 2  standard sodium citrate
for 15min. After another washing, the slides were treated with
antifade solution and then mounted on slides with glass coverslips
and rubber cement. The slides were analysed using a fluorescence
microscope.
Clonogenic assay
A modification of a previously described clonogenic assay was
used to grow MM colony-forming cells (Millar et al, 1988; Rhodes
et al, 1990). Briefly, fresh, low-density BM cells from patients with
MM were fractionated using immunomagnetic beads, and 1 10
5
CD3-, CD33-, and CD14-negative cells were cultured in 0.8%
methylcellulose (Fluka Chemical, Ronkonkoma, NY, USA), con-
taining 10% FCS and RPMI 1640 medium in 1% (volvol
 1)
phytohemagglutinin (PHA) T-cell-conditioned medium, and
irradiated feeder cells obtained from the low-density fraction
of normal donor peripheral blood cells exposed to 70Gy of
g-irradiation, as previously described (Estrov et al, 1994). The
culture mixture was placed in 35-mm Petri dishes (Nunc,
Naperville, IL, USA) in duplicate and maintained at 371C with
Effect of atiprimod on myeloma cells
M Amit-Vazina et al
72
British Journal of Cancer (2005) 93(1), 70–80 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s5% CO2 in air in a humidified atmosphere. Colonies, which were
defined as clusters of more than 40 cells, were counted after 7 days
using an inverted microscope.
To verify the neoplastic nature of the colony-forming cells,
single colonies were microaspirated; the rearranged immuno-
globulin H (IgH) gene in their DNA was amplified by polymerase
chain reaction (PCR), and the product was directly sequenced and
compared to that of the diagnostic BM DNA as previously
described (Estrov et al, 1994). To avoid contamination by residual
effete myeloma cells, only isolated colonies were microaspirated.
The rearranged IgH gene in the DNA from the diagnostic myeloma
BM cells and from individual colonies was amplified using a
modification of a previously described method (Deane and
Norton, 1990). Briefly, cells were placed in 1ml of QuickExtract
DNA Extraction solution 1.0 (Epicentre, Madison, WI, USA) and
lysed in accordance with the manufacturer’s protocol. The DNA
was harvested, and its concentration adjusted with nuclease-free
water. Genomic DNA (1–1.5mg) was added to the reaction
mixture, which contained 10mM dNTP (Promega), 25mM MgCl2
(Proemga), 2.5U of Taq polymerase, Taq polymerase buffer
(Promega), 50pM upstream and downstream primers, and
nuclease-free water in a total volume of 50ml. A separate tube
was prepared for each of the five primers chosen from the first
framework region of the coding strand of representative germline
VH family members amplified together with a JH consensus primer
of the IgH gene. The tubes were denaturated at 941C for 5min and
then subjected to 35 cycles of denaturation at 901C for 1min,
annealing at 661C for 2min, with an extension at 721C for 2min,
and a final extension at 721C for 5min in the Techgene Thermal
Cycler (Techne Inc., Princeton, NJ, USA). A sample of the
amplified DNA was electrophresed in a 2% E-Gel (Invitrogen
Corp., Carlsbad, CA, USA) and visualised by UV illumination. The
bands of interest were excised, and the DNA was purified using
the Wizard SV Gel and PCR Clean-Up System (Promega). Next, the
DNA from the bands was sequenced using a DNA sequencer
(Applied Biosystems, Foster City, CA, USA). The primer for the
coding strand was the appropriate VH family primer, and the
noncoding strand was the JH consensus primer.
RESULTS
Atiprimod suppresses IL-6 production by MM cells
Atiprimod (Atiprimod) was found to downregulate IL-6 produc-
tion (Bradbeer et al, 1996). Therefore, we asked whether Atiprimod
would also inhibit the production of IL-6 in MM cells. We
incubated U266-B1 cells with or without 8mM Atiprimod and
measured IL-6 supernatant levels using an ELISA. Consistent with
previous reports (Catlett-Falcone et al, 1999) we found that U266-
B1 cells produce IL-6, and that the levels of IL-6 in U266-B1 cell
supernatant increased over time. Interleukin-6 supernatant levels
increased from 28pgml
 1 at 1h after incubation to 71, 60, and
222pgml
 1 at 6, 8, and 16h, respectively. Atiprimod attenuated IL-
6 supernatant levels to 23, 42, 53, and 130pgml
 1 at 1, 6, 8, and 16
hours, respectively. Similar results were obtained when U266-B1
cells were incubated in the presence of normal stroma cells or the
stroma cell line KM102 (Table 2). Thus, Atiprimod suppresses
production of IL-6 by U266-B1 cells.
Atiprimod blocks the activation of NF-jB
Since the expression of IL-6 is regulated by NF-kB (Shimizu et al,
1990) and Atiprimod downregulates IL-6 production, we hypothe-
sised that Atiprimod inhibits NF-kB. To test this hypothesis, we
used U266-B1 cells, which constitutively express active NF-kB (Ni
et al, 2001; Bharti et al, 2004) and produce IL-6 (Catlett-Falcone
et al, 1999; Bharti et al, 2003). We incubated U266-B1 cells with
Atiprimod at increasing concentrations for 4h, and with 8mM for 1,
4, 6, 8, and 24h and tested the NF-kB activity in nuclear extracts.
We found that 10mM but not 5mM Atiprimod inhibited constitutive
NF-kB activity, and that 8mM Atiprimod inhibited NF-kB activity
after a prolonged incubation (16h) (Figure 1).
Atiprimod downregulates both IL-6-induced and
constitutive STAT3 phosphorylation in MM cells
Interleukin-6 is produced by MM cells and promotes myeloma cell
proliferation in an autocrine manner (Klein et al, 1995; Chauhan
et al, 1996; Jemal et al, 2003; Anderson, 2004) through
phosphorylation of the signalling protein STAT3 (Kaptein et al,
1996; Hirano et al, 2000; Chatterjee et al, 2002). As Atiprimod
inhibits NF-kB activity and, by doing so, suppresses IL-6
production, we wondered whether Atiprimod downregulates
STAT3 phosphorylation. Using U266-B1 cells, we found that
Atiprimod inhibited STAT3 phosphorylation in a time- and dose-
dependent manner (Figure 2A). After U266-B1 cells were
incubated for 4h with 8mM Atiprimod, the expression of
phosphorylated STAT3 protein was reduced to undetectable levels
(Figure 2A, upper panel). Similarly, DNA binding of activated
STAT3 was reduced by 50% after 2h and completely abolished
after 4h (Figure 2B). Incubation of U266-B1 cells with Atiprimod
at concentrations ranging from 1 to 8mM for 1h significantly
downregulated STAT3 phosphorylation (Figure 2A, lower panel),
suggesting that Atiprimod inhibits the Janus tyrosine kinase
(JAK)-STAT signalling pathway in myeloma cells.
Given that Atiprimod inhibited NF-kB activity at a concentra-
tion of 10mM but not 5mM, and exposure to Atiprimod at a lower
concentration (4mM) for 1h downregulated STAT3 phosphoryla-
tion (Figure 2A), we conclude that Atiprimod inhibited STAT3
phosphorylation directly and that this effect was not mediated
through the inhibition of NF-kB.
We then tested the effects of Atiprimod on the IL-6-responsive
myeloma cell line MM-1 (Deane and Norton, 1990). As expected,
we found that IL-6 induced STAT3 phosphorylation in a dose-
dependent manner at concentrations ranging from 0.5 to
2ngml
 1. However, this effect was significantly attenuated by
Atiprimod (Figure 2C). These results confirm our previous data
showing that that Atiprimod inhibits STAT3 phosphorylation.
Atiprimod inhibits myeloma cell proliferation
As the activation of STAT3 stimulates MM cell proliferation
(Kaptein et al, 1996; Bharti et al, 2004), we sought to determine
whether Atiprimod would reduce the proliferation and metabolic
Table 2 IL-6 supernatant levels (pgml
 1)
+ Normal stroma +KM102
  Atiprimod   Atiprimod   Atiprimod
Normal stroma 650 467
KM102 521 485
MM1 0 0 573 594 583 566
MM1R 0 0 572 524 271 294
U266-B1 227 56 642 514 645 354
OCI-MY5 0 0 714 632 731 686
Cells were incubated for 72h with or without 3mM Atiprimod. The means of
interleukin-6 (IL-6) levels from duplicate wells are depicted.
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sactivity of different MM cell lines. We found that Atiprimod
inhibited U266-B1, OCI-MY5, MM-1, and MM-1R myeloma lines
in a dose- and time-dependent fashion (Figure 3A). Atiprimod at
a concentration of 5mM inhibited MM-1 and MM-1R cell growth
by 96.7 and 72%, respectively, and Atiprimod at a concentration
of 8mM inhibited U266B-1 and OCI-MY5 cells by 99 and 91.5%,
respectively. Atiprimod did not affect the growth of RPMI-8266
myeloma cells.
The antiproliferative effect of atiprimod is not reversed by
IL-6, vascular endothelial growth factor (VEGF), or BM
stroma
We next asked whether IL-6, VEGF, or BM stroma, previously
shown to promote growth and survival of MM cells (Chauhan et al,
1996; Podar et al, 2001; Iwasaki et al, 2002; Menu et al, 2004),
would reverse the inhibitory effect of Atiprimod. To investigate
this, we plated the BM stroma cell line KM102 in 96-well flat-
bottomed plates. After they reached confluence, we added 5 10
4
U266-B1 cells to the wells together with fresh RPMI-1640
supplemented with 10% FCS with or without either IL-6 or VEGF
at 5ngml
 1; the cells were then cultured in the presence or
absence of Atiprimod for 72h. After incubation, U266-B1 cells
were harvested and assayed using MTT as described above. As was
the case in our previous experiments, Atiprimod inhibited U266-
B1 cells in a dose-dependent fashion (Figure 3B and C). Although
Atiprimod suppressed IL-6 production and either reduced or did
not affect soluble IL-6R levels (Tables 2 and 3), neither IL-6 nor
VEGF at a concentration of 5ngml
 1 attenuated the inhibitory
effect of Atiprimod. Coculture of U266-B1 cells with KM102 stroma
cells only partially reversed the inhibitory effect of Atiprimod; the
addition of either IL-6 or VEGF to U266-B1 cells cocultured with
KM102 cells did not affect Atiprimod’s inhibitory effect (Figure 3B
and C). Similar results were obtained with 10ngml
 1 of IL-6 and
VEGF (data not shown).
Atiprimod induces accumulation of MM cells in the
sub-G0/G1 phase of the cell cycle
As Atiprimod blocked STAT3 phosphorylation and inhibited MM
cell proliferation, we asked how this drug affects the progression of
U266-B1 cells through the cell cycle. To answer this question, we
incubated U266-B1 cells with 6mM Atiprimod and performed a cell
cycle analysis using flow cytometry. We found that Atiprimod
induced a sub-G0/G1accumulation with 44.3 and 52.2% of the cells
accumulating in sub-G0 phase at 60 and 90min, respectively
(Figure 4).
Atiprimod downregulates Bcl-2, Bcl-XL, and Mcl-1 protein
levels
The Bcl-2 protein family is involved in the regulation of apoptotic
cell death. Recent studies showed that several myloma cell lines
express Bcl-2 protein at high levels (Pettersson et al, 1992),
providing MM cells with survival advantage (Feinman et al, 1999),
and that activation of STAT3 upregulates the expression of Bcl-XL
(Catlett-Falcone et al, 1999). Furthermore, IL-6 was shown to
upregulate Mcl-1 levels in MM cells through activation of the JAK-
STAT pathway (Puthier et al, 1999). Therefore, we asked whether
Atiprimod would affect the levels of Bcl-2, Bcl-XL, and Bcl-1. As
shown in Figure 5, we found that Atiprimod reduced the levels of
these proteins in U266-B1 cells.
Atiprimod induces apoptotic cell death
As Atiprimod blocked STAT3 activation, inhibited MM cell
proliferation, induced cell cycle arrest in U266-B1 cells at the
G0/G1 phase, and reduced the levels of Bcl-2, Bcl-XL, and Mcl-1, we
hypothesised that Atiprimod induces apoptotic cell death. To test
this hypothesis, we incubated U266-B1 cells at the peak of their
growth for 4h in the presence or absence of 2, 4, or 8mM
Atiprimod. Using annexinV-CY5, we demonstrated that Atiprimod
induced apoptosis in U266-B1 cells in a dose-dependent fashion.
The percentage of cells undergoing apoptotic cell death increased
from 10.89 to 46.27% after exposure to 8mM Atiprimod
(Figure 6A). Interestingly, U266-B1 cells accumulated in sub-G0
phase of the cell cycle after 60 (44.3%) and 90 (52.2%) min of
Atiprimod (M)
NF-B
NF-B
Folds
0 5 10 25 50
4 4 2.5 1.5 1
0 1 4 8 16 24 Time (h)
44 4 4.5 1.5 1 Folds
A
B
Figure 1 Effect of Atiprimod on activation of NF-kB. U266-B1 cells
were incubated for 4h with increasing concentrations of Atiprimod (A)
and with 8mM of Atiprimod for 1, 4, 8, 16, and 24h (B). Nuclear extracts
were prepared, and NF-kB activity was analysed by EMSA, as described in
Materials and Methods.
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sexposure to 6mM Atiprimod (Figure 4). Thus, either not all cells
accumulated in sub-G0 phase undergo apoptosis or different
apoptosis assays yield dissimilar results (Sailer et al, 1988; Clarke
et al, 2000).
Atiprimod induces apoptosis by activating the caspase
pathway
To validate these findings, we incubated U266-B1 cells with or
without 8mM Atiprimod in the presence or absence of 50mM of the
caspase inhibitor Ac-DEVD-CHO and used the TUNEL assay to
detect apoptotic cells. As shown in Figure 6B, we found that
Atiprimod induced apoptotic cell death in 90% of U266-B1 cells,
and the addition of c-DEVD-CHO blocked Atiprimod-induced
apoptosis.
Apoptosis is executed through the activation of a family of
cystein proteases named caspases, which are synthesised as latent
intracellular proenzymes. Cleavage of the procaspase forms
converts them into biologically active caspases (Strasser et al,
2000; Orlowski and Baldwin, 2002). We chose to study the effect
of Atiprimod on the activation of caspase 3, the downstream
‘executioner’ caspase (Nicholson, 1999) in U266-B1 cells. As shown
in the Western immunoblot in the upper panel of Figure 6C,
Atiprimod induced procaspase 3 cleavage in a time-dependent
Time (min)
p-STAT3
-Actin
-Actin
-Actin
STAT 3
Atiprimod (M)
Atiprimod (2.5 M)
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STAT 3
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IL-6(ng ml–1)
pSTAT3
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0 0.5 12 48
12 4 8
Time (h)
0
0
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3 3 2.5 1.5 1 1 Folds
–––––+++++
0 0.5 1 1.5 2 0 0.5 1 1.5 2
A
B
C
Figure 2 (A) Effect of Atiprimod on constitutive STAT3 phosphorylation. U266-B1 (1 10
7 cellsml
 1) were incubated in RPMI 1640 supplemented with
10% FCS with or without 8mM Atiprimod for 5–240min (upper panel). In a separate experiment, 1 10
7 U266-B1 cells were incubated with or without
increasing concentrations of Atiprimod for 1h(lower panel). Signal transducer and activator of transcription (STAT) 3 and phosphorylated (p) STAT3 and
were detected by Western immunoblotting as described in Materials and Methods. Equal loading of protein was confirmed by using anti-b-actin antibodies.
(B) Effect of Atiprimod on binding of DNA with activated STAT3. U266-B1 cells were incubated with 8mM Atiprimod for 0.5, 1, 2, 4, and 6h. Nuclear
extracts were labelled with hSIE probe and STAT3-DNA binding was analysed by EMSA, as described in Materials and Methods. (C) Effect of Atiprimod on
IL-6-induced STAT3 phosphorylation. MM-1 cells (1 10
7 cellsml
 1) were incubated for 2h in RPMI 1640 supplemented with 10% FCS and increasing
concentrations of IL-6 with or without 2.5mM Atiprimod.
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smanner, with the maximum effect achieved after 4h. Furthermore,
incubation of U266-B1 cells for 1h with Atiprimod induced a dose-
dependent increase in caspase 3 cleavage (Figure 6C, lower panel).
Activated caspase 3 abrogates the effect of substrates that
protect cellular integrity, such as the DNA-repair enzyme
PARP (Nicholson, 1999; Kraus and Lis, 2003). When we
exposed the cells to Atiprimod, we found a dose-dependent
increase in cleaved PARP protein levels, with the maximum
effect achieved at a concentration of 8mM (Figure 6C, lower
panel).
Atiprimod inhibits MM colony-forming cell proliferation
In light of these results, we postulated that Atiprimod would also
inhibit the proliferation of primary MM cells. To investigate this,
we first studied the effect of Atiprimod on fresh low-density
marrow cells from three patients with MM. We incubated the cells
with increasing concentrations of Atiprimod and analysed its effect
using the MTT assay. As shown in Figure 7A, we found that
Atiprimod suppressed the metabolic activity of MM cells in a dose-
dependent manner with no activity detected at 8ı `M. We then asked
whether Atiprimod would also inhibit myeloma colony-forming
cells. We obtained BM cells from five patients with newly
diagnosed, untreated MM (Table 1). As depicted in Figure 7B,
we found that Atiprimod suppressed MM colony-forming cell
growth in a dose-dependent manner, reaching 85% suppression at
4mM and 100% at 8mM.
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Figure 3 (A) Effect of Atiprimod on MM cell lines. Upper panel: MM-1, U266-B1, OCI-M5, MM-1R, and RPMI-8266 (5 10
4) cells were incubated in
RPMI 1640 supplemented with 10% FCS with or without increasing concentrations of Atiprimod for 72h. Cells were harvested and their metabolic activity
and viability were determined using the MTT assay. Data are presented as the mean7standard deviation of optical density (OD) measurements of six wells.
Lower panel: MM-1, U266-B1, OCI-M5, and MM-1R cells (5 10
4) were incubated with 4mM Atiprimod for 24, 48, and 72h. Cells were harvested and their
metabolic activity and viability were determined using the MTT assay. Data are presented as a percent of OD of cells cultured without Atiprimod at the
same time point (control). (B, C) Effect of IL-6, VEGF, and BM stroma on Atiprimod-induced inhibition of U266-B1 cells. These cells were cultured alone or
with adherent KM102 stroma cells, with or without either IL-6 (B) or VEGF (C) at 5ngml
 1, and in the presence of increasing concentrations of Atiprimod.
After 72h, U266-B1 cells were harvested and analysed using the MTT assay. The data are presented as the mean7standard deviation of OD measurements
of five wells.
Table 3 Soluble interleukin-6 receptor (IL-6R) supernatant levels
(pgml
 1)
+Normal stroma +KM102
  Atiprimod   Atiprimod   Atiprimod
Normal stroma 650 467
KM102 521 485
MM1 0 0 573 594 583 566
MM1R 0 0 572 524 271 294
U266-B1 27 0 642 514 645 354
OCI-MY5 0 0 714 632 731 686
Cells were incubated for 72h with or without 3mM Atiprimod. The means of soluble
IL-6R levels from duplicate wells are depicted.
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sMultiple myeloma colonies were identified by their morpholo-
gical characteristics, as depicted in the upper panel of Figure 7C.
To verify that the MM colony-forming cells originated from the
neoplastic clone, single colonies were microaspirated at random,
and the rearranged IgH gene in DNA from the original BM sample
and from individual MM colonies was amplified via PCR using
primers chosen from the first framework region of the coding
strand of representative germline VH family members and a JH
consensus primer. As shown at the bottom of Figure 7C, all
analysed colonies showed an IgH gene rearrangement identical to
that of the diagnostic marrow cells. Sequence analysis of colony-
derived DNA showed a 90% homology with the original MM cell
DNA, confirming the neoplastic clonal origin of the colony-
forming cells.
DISCUSSION
Several growth factors and cytokines stimulate MM cell prolifera-
tion by activating various signalling pathways (Zhang et al, 2003;
Giuliani et al, 2004). Of those molecules, IL-6 has been studied
extensively, and its pathophysiologic effects in MM have been
well characterised (Klein et al, 1995; Chauhan et al, 1996). Since
Atiprimod downregulates serum IL-6 levels (Bradbeer et al, 1996),
we tested Atiprimod’s effect on U266-B1 cells, known to consti-
tutively produce IL-6 (Catlett-Falcone et al, 1999), and found that
Atiprimod suppressed IL-6 production in a time-dependent
manner.
Since IL-6 expression is regulated by NF-kB (Shimizu et al,
1990), we investigated whether Atiprimod inhibits NF-kB activity.
The NF-kB transcription factor family is an important modulator
of cellular proliferation, suppression of apoptosis, enhancement of
tumour cell invasiveness, and induction of angiogenesis (Orlowski
and Baldwin, 2002). The antitumour activity of the proteasome
inhibitor bortezomab in MM is thought to be mediated through
the inhibition of NF-kB (Voorhees et al, 2003). We recently found
that fresh BM cells obtained from MM patients express constitu-
tively active NF-kB and STAT3 (Bharti et al, 2004). Furthermore,
MM patients’ myeloma cells constitutively produce IL-6 (Catlett-
Falcone et al, 1999; Bharti et al, 2003). Thus, it is possible that
constitutively activated NF-kB induces the production of IL-6,
which in turn activates STAT3 (Kaptein et al, 1996; Chatterjee et al,
2002) and MM cell proliferation. Therefore, we wondered whether
Atiprimod inhibits NF-kB activity and, by doing so, downregulates
constitutive production of IL-6. Using U266-B1 cells, which
express constitutively active NF-kB and STAT3 (Bharti et al,
2004) and produce IL-6, we found that Atiprimod inhibited NF-kB
activation.
Since Atiprimod inhibited NF-kB and IL-6 production, we
wondered whether Atiprimod also downregulated IL-6 signalling.
Using U266-B1 cells, we found that Atiprimod inhibited STAT3
phosphorylation after a shorter incubation and at concentrations
lower than those required for the inhibition of NF-kB. As these
results suggested that Atiprimod directly inhibited STAT3
phosphorylation, we used MM-1 cells in which the JAK-STAT
pathway is activated upon exposure to exogenous IL-6 (Chatterjee
et al, 2002). As in our previous experiments with U266-B1 cells, we
found that Atiprimod inhibited the IL-6-induced STAT3 phos-
phorylation in MM-1 cells in a time- and dose-dependent manner.
These results suggest that Atiprimod suppresses STAT3 phos-
phorylation directly, and that this effect is not dependent on
the inhibition of NF-kB. Nevertheless, the ability of Atiprimod
to inhibit NF-kB, a proven target in myeloma treatment, suggests
that Atiprimod might also inhibit myeloma cells through
that mechanism, provided that higher concentrations of this drug
are used.
As Atiprimod blocked STAT3 phosphorylation and thus the
JAK-STAT pathway, we tested the effect of Atiprimod on MM cell
proliferation. As expected, Atiprimod inhibited several myeloma
cell lines. Specifically, Atiprimod induced accumulation of
myeloma cells at the sub-G0/G1 phase of the cell cycle. Atiprimod
inhibited MM-1 and the dexamethasone-resistant MM-1R cells in
the absence of exogenous IL-6. Although small amounts of IL-6
present in FCS could have stimulated the JAK-STAT pathway in
these cells, Atiprimod might have blocked other signalling
pathways involved in stimulating the proliferation of MM-1 and
OCI-MY5 cells.
We then asked whether Atiprimod could inhibit the pro-
liferation of primary MM cells. Using the myeloma colony
culture assay, we found that Atiprimod suppressed the growth of
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Figure 4 Effect of Atiprimod on the cell cycle status of U266-B1 cells. These cells were incubated in RPMI 1640 supplemented with 10% FCS with or
without 6mM Atiprimod, and cell cycle analysis was performed as described above. The percentages of cells in sub-G0,G 0/G1, S, and G2M phases of the cell
cycle are given.
Bcl-2
-Actin
Bcl-XL
Atiprimod (M)
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01248
Figure 5 Effect of Atiprimod on Bcl-2, Bcl-XL, and Mcl-1 protein levels.
U266-B1 cells were incubated for 2h with Atiprimod at increasing
concentrations. The levels of Bcl-2, Bcl-XL, and Mcl-1 were detected by
Western immunoblotting. The results shown here demonstrate a dose-
dependent decrease in the levels of Bcl-2, Bcl-XL, and Mcl-1.
Effect of atiprimod on myeloma cells
M Amit-Vazina et al
77
British Journal of Cancer (2005) 93(1), 70–80 & 2005 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
smyeloma colony-forming cells of fresh BM samples obtained
from five patients with newly diagnosed MM in a dose-dependent
fashion.
As discussed above, several factors besides IL-6 contribute to
myeloma cell proliferation. In particular, VEGF and marrow
stroma are major players in this process (Chauhan et al, 1996;
Anderson, 1999; Podar et al, 2001; Iwasaki et al, 2002).
VEGF stimulates MM cells by triggering activation of the JAK-
STAT pathway (Rabinovitch et al, 1993) and exerts a proangio-
genic effect that is thought to play a role in the pathogenesis of
MM (Anderson, 1999). Interestingly, the levels of VEGF have been
found to correlate with disease stage and progression (Iwasaki
et al, 2002). Bone marrow stroma also contributes to the
myelomatous process through the production of stimulating
cytokines (Chauhan et al, 1996). Additionally, according to a
recent study, MM cells become independent of the STAT3 pathway
in the presence of BM stroma (Chatterjee et al, 2002). Therefore,
we sought to determine whether IL-6, VEGF, and BM stroma
interfere with the antiproliferative effect of Atiprimod. We found,
however, that neither IL-6 nor VEGF negated the effect of
Atiprimod, and that the BM stroma cell line KM102 only partially
reversed Atiprimod’s inhibitory effect.
The activation of STAT3 in myeloma cells results in the
upregulation of antiapoptotic proteins of the Bcl-2 family, such
as Bcl-2, Bcl-XL, and Mcl-1, thus providing MM cells with a
survival advantage (Pettersson et al, 1992; Catlett-Falcone et al,
1999; Feinman et al, 1999; Puthier et al, 1999). As Atiprimod
suppresses STAT3 phosphorylation, we asked how it would affect
Bcl-2, Bcl-XL, and Mcl-1 protein levels. We found that Atiprimod
downregulated the levels of Bcl-2, Bcl-XL, and Mcl-1, and induced
apoptotic cell death in U266-B1 myeloma cells. Atiprimod’s
proapoptotic effect was blocked by the caspase inhibitor Ac-
DEVD-CHO, suggesting that apoptosis was induced through the
activation of the caspase pathway. Indeed, exposure of U266-B1
myeloma cells to Atiprimod resulted in the activation of the
downstream executioner caspase 3 and subsequent cleavage of the
DNA repair enzyme PARP.
Taken together, our data show that Atiprimod blocks STAT3
phosphorylation and the activation of NF-kB, inhibits cellular
proliferation, causes cell cycle arrest, and induces apoptosis in MM
cells. As Atiprimod was well tolerated in patients with rheumatoid
arthritis, phase I studies of Atiprimod in patients with MM are
warranted.
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Figure 6 Atiprimod induces apoptosis in myeloma cells. (A) U266-B1 cells were incubated with or without 2, 4, or 8mM Atiprimod for 4h. The fraction of
cells undergoing apoptosis was detected by annexin V-CY5. The percentages in each frame indicate the apoptotic cell fraction. (B) U266-B1 cells were
incubated with (b, d) or without (a, c) 8mM Atiprimod and with (c, d) or without (a, b) 50mM Ac-DEVD-CHO. After incubation, cytospun cells were stained
with TUNEL. Yellow-appearing cells (apoptotic cells) were detected after exposure to Atiprimod (b). The addition of Ac-DEVD-CHO, which by itself did
not affect cell morphology (c) reversed this process (d). (C) Atiprimod activates caspase 3 and cleaves PARP. U266-B1 cells were incubated with 8mM
Atiprimod for 0, 5, 10, 20, 120, and 240min (upper panel) and Atiprimod at increasing concentrations for 1h (lower panel). The levels of procaspase 3,
caspase 3, and uncleaved and cleaved PARP were detected by Western immunoblotting. The results shown here demonstrate a time-dependent increase in
the cleaved caspase 3 level (upper panel) and a dose-dependent increase in the cleaved caspase 3 and cleaved PARP levels (lower panel).
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Figure 7 Atiprimod inhibits primary MM cell proliferation. (A) Low-density BM cells from three patients with MM and incubated in the presence of
Atiprimod at concentrations ranging from 1 to 8mM and analysed using the MTT assay. (B) The effect of Atiprimod on MM colony-forming cells was studied
on marrow cells from five patients with MM. After fractionation, myeloma cells were cultured in the presence of Atiprimod at concentrations ranging from 1
to 8mM. Multiple myeloma colonies are presented as percentages of control (the mean number of colonies obtained from patients 1 through 5 in the
absence of Atiprimod was 82, 243, 133, 179, and 467, respectively). (C) The top panel depicts two typical MM colonies. Of note are the large cells with
myeloma cell morphology at the periphery of the colony. The middle panel shows the products of PCR amplification of DNA from the original marrow of
patient 2 and from seven single colonies microaspirated at random using VH3–JH consensus primers. The myeloid leukaemia cell line OCIM2 was used as a
negative control (Neg. Cont.). Actin was used as an amplification control (MW denotes molecular weight). The lower panel shows the nucleotide sequences
of amplified products of DNA from the D region of the diagnostic marrow (1) and of three different colonies (2–4). The middle and lower panels
demonstrate that the MM colonies originated from the neoplastic clone.
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